{"doi":"10.3390/ph17040418","title":"Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease","abstract":"<jats:p>Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Although the prevalence of other complications of diabetes is falling, the number of diabetic patients with end-stage kidney disease in need of kidney replacement therapy is rising. In addition, these patients have extremely high cardiovascular risk. It is more than evident that there is a high unmet treatment need in patients with diabetic kidney disease. Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist used for treating diabetic kidney disease. It has predominant anti-fibrotic and anti-inflammatory effects and exhibits several renal and cardiac protective effects. This review article summarizes the current knowledge and future prospects of finerenone in treating patients with kidney disease.</jats:p>","journal":"Pharmaceuticals","year":2024,"id":643090,"datarank":0.4887144807032224,"base_score":3.258096538021482,"endowment":3.258096538021482,"self_citation_contribution":0.4887144807032224,"citation_network_contribution":0.0,"self_endowment_contribution":0.4887144807032224,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":25,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1673118,"name":"Sebastjan Bevc","orcid":null,"position":1,"is_corresponding":false},{"id":1673119,"name":"Radovan Hojs","orcid":null,"position":2,"is_corresponding":false},{"id":1673120,"name":"Robert Ekart","orcid":"0000-0002-7395-752X","position":3,"is_corresponding":false},{"id":1673117,"name":"Nejc Piko","orcid":"0000-0003-1314-4428","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease","abstract":"<jats:p>Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Although the prevalence of other complications of diabetes is falling, the number of diabetic patients with end-stage kidney disease in need of kidney replacement therapy is rising. In addition, these patients have extremely high cardiovascular risk. It is more than evident that there is a high unmet treatment need in patients with diabetic kidney disease. Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist used for treating diabetic kidney disease. It has predominant anti-fibrotic and anti-inflammatory effects and exhibits several renal and cardiac protective effects. This review article summarizes the current knowledge and future prospects of finerenone in treating patients with kidney disease.</jats:p>","is_dataset_classified":null,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38675379","pmcid":"PMC11054947","openalex_id":"https://openalex.org/W4393201708","authors":[],"funders":[],"total_grants":0,"fwci":6.4039,"citation_percentile":0.97387997,"influential_citations":0,"citation_trend":[{"year":2024,"count":6},{"year":2025,"count":9},{"year":2026,"count":9}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1424-8247/17/4/418/pdf?version=1711464737","host_type":"journal"},{"url":"https://www.mdpi.com/1424-8247/17/4/418/pdf?version=1711464737","host_type":"publisher"},{"url":"https://www.mdpi.com/1424-8247/17/4/418/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/ph17040418","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38675379","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11054947","host_type":"repository"},{"url":"https://doaj.org/article/46f8395aeffd47e19dfe3d1aa48c1fa7","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11054947/pdf/pharmaceuticals-17-00418.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11054947","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11054947?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Hormonal Regulation and Hypertension","Electrolyte and hormonal disorders","Ion Transport and Channel Regulation"],"mesh_terms":[],"keywords":["Medicine","Kidney disease","Diabetes mellitus","Disease","Mineralocorticoid receptor","Kidney","Intensive care medicine","Renal replacement therapy","Internal medicine","Bioinformatics","Endocrinology","Aldosterone","Diabetes","Chronic Kidney Disease","Finerenone"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-08T12:37:14.182936Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}